Genentech Settles FCA Suit Over Cancer Drug For $20M

Law360, New York (November 30, 2011, 4:29 PM EST) -- A Pennsylvania federal court on Tuesday dismissed a False Claims Act suit accusing Genentech Inc. of fraudulently marketing its non-Hodgkin lymphoma drug Rituxan, after the California-based biotechnology company settled the suit for $20 million.

The settlement, which calls for Genentech to pay the $20 million to the U.S., was reached last week, according to court documents. U.S. District Judge Paul Diamond dismissed the suit with prejudice, putting an end to the eight-year case.

The qui tam suit was brought by former Genentech employee John Underwood, who...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

JOHN UNDERWOOD v. GENETECH, INC. et al


Case Number

2:03-cv-03983

Court

Pennsylvania Eastern

Nature of Suit

Other Statutory Actions

Judge

PAUL S. DIAMOND

Date Filed

July 3, 2003

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.